Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Fennec Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Fennec Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Fennec Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Fennec Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Fennec Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Fennec Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Fennec Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Fennec Pharmaceuticals has no long term commitments.
This treemap shows a more detailed breakdown of
Fennec Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Fennec Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of Fennec Pharmaceuticals Inc. (alternate name Adherex Technologies Inc) since July 2009 and serves as its President. Mr. Raykov is a General Partner at DCML, a private investment partnership. Mr. Raykov has financial expertise and experience with Fennec. He served as a General Partner of Alchem Investment Partners from January 2006 to December 2007, an event driven hedge fund. He was a Portfolio Manager Alchem Partners. Mr. Raykov was a Portfolio Manager and Securities Analyst for John A. Levin & Co. Event Driven Fund from 2002 to 2005. Mr. Raykov was a Securities Analyst for the Merger Fund at Tiedemann Investment Group from 1999 to 2002 and an Investment Banking Analyst at Bear Stearns from 1998 to 1999. He served as Chairman of Fennec Pharmaceuticals Inc. from August 2013 to December 9, 2015 and has been its Director since July 2009. He served as an Independent Director at Wesdome Gold Mines Ltd. since August 26, 2013. Mr. Raykov has been an Independent Director at Amarillo Gold Corp. since July 19, 2013. Mr. Raykov earned a BS in Business Administration from the University of North Carolina at Chapel Hill.
Rosty's compensation has increased whilst company is loss making.
Rosty's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Fennec Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
CEO & Director
Chief Financial Officer
President of Pharstat Inc
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Fennec Pharmaceuticals board of directors is about average.
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.